Medulloblastomas: Review;Les médulloblastomes: revue générale

Revue Neurologique

Volumn 167, Issue 5, 2011, Pages 431-448

  Taillandier, L ^a   Blonski, M ^a   Carrie, C ^b   Bernier, V ^c   Bonnetain, F ^d   Bourdeaut, F ^e   Thomas, I C ^f   Chastagner, P ^g   Dhermain, F ^h   Doz, F ^e   Frappaz, D ^b   Grill, J ^h   Guillevin, R ⁱ   Idbaih, A ⁱ   Jouvet, A ^j   Kerr, C ^k   Donadey, F L ⁱ   Padovani, L ^l   Pallud, J ^m   Sunyach, M P ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b CENTRE LÉON BÉRARD   (France)

^c Centre A Vautrin   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e INSTITUT CURIE   (France)

^f HÔPITAL SAINT ANDRÉ   (France)

^g HÔPITAL D ENFANTS   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j HÔPITAL NEUROLOGIQUE   (France)

^k CENTRE VAL D AURELLE   (France)

^l TIMONE HOSPITAL   (France)

^m CENTRE HOSPITALIER SAINTE ANNE   (France)

more..

Author keywords

Chemotherapy; Cognition; Medulloblastoma; Quality of life; Radiotherapy; Surgery

Indexed keywords

BONE DISEASE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CEREBELLUM TUMOR; CHEMOSENSITIVITY; CHILDHOOD CANCER; COGNITIVE DEFECT; HISTOPATHOLOGY; MEDULLOBLASTOMA; MOLECULAR BIOLOGY; NEUROENDOCRINE DISEASE; NEUROLOGIC DISEASE; NEUROSURGERY; RADIOSENSITIVITY; REVIEW; SURVIVAL RATE;

CEREBELLAR NEOPLASMS; HUMANS; MEDULLOBLASTOMA; TREATMENT OUTCOME;

EID: 79957692898     PISSN: 00353787     EISSN: 00353787     Source Type: Journal    
DOI: 10.1016/j.neurol.2011.01.014     Document Type: Review

References (131)

1. Back M, Ahern V, Berry M, Borg M, Sexton M, Cameron F, et al. Importance of radiation time and dose factors on outcome for childhood medulloblastoma. Australas Radiol 2005;49:298-303. (Pubitemid 41097966)
2. Bailey C, Gnekow A, Wellek S, Jones M, Round C, Brown J, et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995;25:166-78.
3. Barel D, Avigad S, Mor C, Fogel M, Cohen IJ, Zaizov R. A novel germ-line mutation in the noncoding region of the p53 gene in a Li-Fraumeni family. Cancer Genet Cytogenet 1998;103:1-6. (Pubitemid 28237065)
4. Bauchet L, Rigau V, Mathieu-Daude H, Fabbro-Peray P, Palenzuela G, Figarella-Branger D, et al. Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol 2009;92:87-98.
5. Becker LE, Jay V. Tumors of the central nervous system in children. In: Deutsh M, editor. Management of childhood brain tumors. Assinippi Park: Norwell; 1990. p. 5-52.
6. Bernier V. Technical aspects in cerebrospinal irradiation. Pediatr Blood Cancer 2004;42:447-51. (Pubitemid 38524476)
7. Bloom HJG, Bessel EM. Medulloblastoma in adults: a review of 47 patients treated betwenn 1952 and 1981. Int J Radiat Oncol Biol Phys 1990;18:763-72.
8. Brandes AA, Franceschi E, Tosoni A, Reni M, Gatta G, Vecht C, et al. Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol 2009;71:165-79.
9. Brown HG, Kepner JL, Perlman EJ, Friedman HS, Strother DR, Duffner PK, et al. Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 2000;59:857-65.
10. Callu D, Laroussinie F, Kieffer V, Notteghem P, Zerah M, Hartmann O, et al. Remediation of learning difficulties in children after treatment for a cerebellar medulloblastoma: a single-case study. Dev Neurorehabil 2008;11:16-24.
11. Callu D, Puget S, Boddaert N, Viguier D, Kieffer V, Bulteau C, et al. Injuries to inferior vermis and dentate nuclei predict poor neurological and neuropsychological outcome in children with malignant posterior fossa tumors. Cancer 2009;115:1338-13447.
12. Callu D, Viguier D, Laroussinie F, Puget S, Boddaert N, Kieffer V, et al. Cognitive and academic outcome after benign or malignant cerebellar tumor in children. Cogn Behav Neurol 2009;22:270-8.
13. Campbell AN, Chan HS, Becker LE, Daneman A, Park TS, Hoffman HJ. Extra-cranial metastases in childhood primary intracranial tumors. A report of 21 cases and review of the literature. Cancer 1984;54:974-81.
14. Carrie C, Alapetite C, Mere P, Aimard L, Pons A, Kolodie H, et al. Quality control of radiotherapeutic treatment of medulloblastoma in a multicentric study: the contribution of radiotherapy technique to tumor relapse. The French Medulloblastoma Group. Radiother Oncol 1992;24:77-81.
15. Carrie C, Lasset C, Blay JY, Negrier S, Bouffet E, Barbet N, et al. Medulloblastomas in adults: survival and prognostic factors. Radiather Oncol 1993;29:301-7. (Pubitemid 24025351)
16. Carrie C, Lasset C, Alapetite C, Haie-Meder C, Hoffstetter S, Demaille MC, et al. Multivariate analysis of prognostic factors in adult patients with medulloblastomas. Cancer 1994;74:2352-60. (Pubitemid 24322292)
17. Carrie C, Hoffstetter S, Gomez F, Moncho V, Doz F, Alapetite C, et al. Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP). Int J Radiat Oncol Biol Phys 1999;45:435-9. (Pubitemid 29408560)
18. Carrie C, Muracciole X, Gomez F, Habrand JL, Benhassel M, Mege M, et al. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French MSFOP 98 protocol. Int J Radiat Oncol Biol Phys 2005;63:711-6. (Pubitemid 41400056)
19. Carrie C, Grill J, Figarella-Branger D, Bernier V, Padovani L, Habrand JL, et al. Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standardrisk medulloblastoma: long-term results of MSFOP 98. J Clin Oncol 2009;27:1879-83.
20. Catsman-Berrevoets CE, Van Dongen HR, Mulder PG, Paz y Geuze D, Paquier PF, Lequin MH. Tumor type and size are high-risk factors for the syndrome of "cerebellar" mutism and subsequent dysarthria. J Neurol Neurosurg Psychiatry 1999;67:755-7.
21. Chan AW, Tarbell NJ, Black PM, Louis DN, Frosch MP, Ancukiewicz M, et al. Adult medulloblastomas: prognstic factors and patterns of relapse. Neurosurgery 2000;47:623-32. (Pubitemid 32044708)
22. Chang CH, Housepian EM, Herbert Jr C. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 1969;93:1351-9.
23. Chumas P, Tyagi A, Livingston J. Hydrocephalus-what's new? Arch Dis Child Fetal Neonatal Ed 2001;85:F149-54.
24. Chumas P, Sainte-Rose C, Cinalli G, Roux FE, Maixner R, Chumas PD, Mansour M, et al. Management of hydrocephalus in pediatric patients with posterior fossa tumors: the role of endoscopic third ventriculostomy. J Neurosurg 2001;95:791-7. (Pubitemid 33043352)
25. Clifford SC, Lusher ME, Linsey JC, Langdon JA, Gilbertson RJ, Straughton D, et al. Wnt/wingless pathway activation and chromosome 6 loss characterize a distinct molecular subgroup of medulloblastomas associated with a favourable prognosis. Cell Cycle 2006;5:2666-70.
26. Cornu P, Chatellier G, Fauchon F, Foncin JF, Faillot T, Dorwling-Carter D, et al. Pronostic des médulloblastomes de l'adulte. Neurochirurgie 1990;36:218-24.
27. Coulbois S, Civit T, Grignon Y, Taillandier L, Girard F, Marchal JC, et al. Médulloblastomes de l'adulte. À propos de 22 cas: revue de la littérature et perspectives thérapeutiques. Neurochirurgie 2001;47:6-12.
28. De Bont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R. Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro Oncol 2008;10:1040-60.
29. Deutsch M, Thomas PR, Krischer J, Boyett JM, Albright L, Aronin P, et al. Results of a prospective randomized trial comparing standard-dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology Group Study. Pediatr Neurosurg 1996;24:167-76.
30. Duffner PK, Cohen ME. The long-term effects of central nervous system therapy on children with brain tumors. Neurol Clin 1991;9:479-95.
31. Duffner PK, Cohen ME, Voorhess ML, MacGillivray MH, Brecher ML, Panahon A, Gilani BB. Long-term effects of cranial irradiation on endocrine function in children with brain tumors. A prospective study. Cancer 1985;56:2189-93. (Pubitemid 16236592)
32. Duffner PK, Horowitz ME, Krischer JP, Burger PC, Cohen ME, Sanford RA, et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol 1999;1:152-61.
33. Dunkel IJ, Gardner SL, Garvin Jr JH, Goldman S, Shi W, Finlay JL. High-dose carboplatin, thiotepa and etoposide with autologus stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro Oncol 2010;12:297-303.
34. Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ. What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 2003;7:53-66. (Pubitemid 36519473)
35. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, et al. United Kingdom Children's Cancer Study Group Brain Tumor Committee. Beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumor Committee. J Clin Oncol 2005;23:7951-7. (Pubitemid 46657395)
36. Entz-Werle N, De Carli E, Ducassou S, Legrain M, Grill J, Dufour C. Medulloblastoma: What is the role of molecular genetics? Expert Rev Anticancer Ther 2008;8:1169-81.
37. Entz-Werle N, Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, et al. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 2009;218:86-94.
38. Evans AE, Jenkin RD, Sposto R, Ortega JA, Wilson CB, Wara W, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990;2:572-82. (Pubitemid 20113683)
39. Fattet S, Haberler C, Legoix P, Lellouch-Tubiana A, Lair S, Manie E, et al. Beta-Catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles and clinical characteristics. J Pathol 2009;218:86-94.
40. Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JY, Tamayo P, Pomeroy SL. Combining gene expression profiles ans clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 2004;22:994-8. (Pubitemid 41095030)
41. Ferrante L, Mastronardi L, Celli P, Acqui M, Cervoni L, Fortuna A. Medulloblastoma in adulthood. J Neurosurg Sci 1991;35:23-30.
42. Fouladi M, Gajjar A, Boyett JM, Walter AW, Thompson SJ, Merchant TE, et al. Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 1999;17:3234-7. (Pubitemid 29470657)
43. Fouladi M, Langston J, Mulhern R, Jones D, Xiong X, Yang J, et al. Silent lacunar lesions detected by magnetic resonance imaging of children with brain tumors: a late sequela of therapy. J Clin Oncol 2000;18:824-31. (Pubitemid 30106613)
44. Fukunaga-Johnson N, Lee JH, Sandler HM, Robertson P, McNeil E, Goldwein JW. Patterns of failure following treatment for medulloblastoma: is it necessary to treat the entire posterior fossa? Int J Radiat Oncol Biol Phys 1998;42:143-6.
45. Gajjar A, Fouladi M, Walter AW, Thompson SJ, Reardon DA, Merchant TE, et al. Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncol 1999;17:1825-8. (Pubitemid 29269253)
46. Gentet JC, Bouffet E, Doz F, Tron P, Roche H, Thyss A, et al. Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study. J Neurosurg 1995;82:608-14.
47. Gessi M, Madema E, Guzzetti S, Cefalo G, Massimino M, Solero CL, et al. Radiation-induced glioblastoma in a medulloblastoma patient: a case report with molecular features. Neuropathology 2008;28:633-9.
48. Giangaspero F, Bigner SH, Kleihues J, Pietsch T, Trojanowski JQ. Medulloblastoma. In: Kleihues P, Cavenee WK: World Health Organisation classification of tumors. Pathology and genetics: tumors of the nervous system. Lyon: IARC Press; 2000.
49. Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004;5:209-18. (Pubitemid 38391216)
50. Giordana MT, Schiffer P, Lanotte M, Girardi P, Chio A. Epidemiology of adult medulloblastoma. Int J Cancer 1999;80:689-92. (Pubitemid 29066279)
51. Goldwein JW, Radcliffe J, Johnson J, Moshang T, Packer RJ, Sutton LN, et al. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiat Oncol Biol Phys 1996;34:899-904. (Pubitemid 26089229)
52. Gould VE, Rorke LB, Jansson DS, Molenaar WM, Trojanowski JQ, Lee VM, et al. Primitive neuroectodermal tumors of the central nervous system express neuroendocrine markers and may express all classes of intermediate filaments. Hum Pathol 1990;21:245-52. (Pubitemid 20081223)
53. Greenberg HS, Chamberlain MC, Glantz MJ, Wang S. Adult medulloblastoma: multiagent chemotherapy. Neuro Oncol 2001;3:29-34. (Pubitemid 33685583)
54. Grill J, Bhangoo R. Recent development in chemotherapy of paediatric brain tumours. Curr Opin Oncol 2007;19:612-5. (Pubitemid 47508870)
55. Grill J, Renaux VK, Bulteau C, Viguier D, Levy-Piebois C, Sainte-Rose C, Dellatola, s G, Raquin MA, Jambaque I, Kalifa C. Longterm intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int J Radiat Oncol Biol Phys 1999;45:137-45. (Pubitemid 29380085)
56. Grill J, Kieffer V, Kalifa C. Measuring the neurocognitive side effects of irradiation in children with brain tumors. Pediatr Blood Cancer 2004;42:452-6. (Pubitemid 38524477)
57. Grill J, Viguier D, Kieffer V, Bulteau C, Sainte-Rose C, Hartmann O, et al. Critical risk factors for intellectual impairment in children with posterior fossa tumors: the role of cerebellar damage. J Neurosurg 2004;101:152-8. (Pubitemid 39426188)
58. Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A, et al. Myc messenger RNA expresion predicts survival outcome in childhood primitive neurectodermal tumor/medulloblastoma. Clin Cancer Res 2001;7:2425-33. (Pubitemid 32751645)
59. Hazuka MB, DeBiose DA, Henderson RH, Kinzie JJ. Survival results in adult patients treated for medulloblastomas. Cancer 1992;69:2143-8.
60. Hoffmann HJ, Hendrick EB, Humphreys RP. Metastasis via ventriculoperitoneal shunt in patients with medulloblastomas. J neurosurg 1976;44:562-6.
61. Hoppe-Hirsch E, Renier D, Lellouch-Tubiana A, Sainte-Rose C, Pierre-Kahn A, Hirsch JF. Medulloblastoma in childhood: progressive intellectual deterioration. Childs Nerv Syst 1990;6:60-5. (Pubitemid 20165052)
62. Hoppe-Hirsch E, Brunet L, Laroussinie F, Cinalli G, Pierre-Kahn A, Renier D, Sainte-Rose C, Hirsch JF. Intellectual outcome in children with malignant tumors of the posterior fossa: influence of the field of irradiation and quality of surgery. Childs Nerv Syst 1995;11:340-5.
63. Hoppe-Hirsch E, Laroussinie F, Brunet L, Sainte-Rose C, Renier D, Cinalli G, Zerah M, Pierre-Kahn A. Late outcome of the surgical treatment of hydrocephalus. Childs Nerv Syst 1998;14:97-9. (Pubitemid 28269634)
64. Huang E, The BS, Strother DR, Davis QG, Chiu JK, Lu H, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 2002;52:599-605. (Pubitemid 34158719)
65. Hubbard JL, Scheithauer BW, Kispert DB, Carpenter SM, Wick MR, Laws ER. Adult cerebellar medulloblastomas: the pathological, radiographic and clinical disease spectrum. J Neurosurg 1989;70:536-44. (Pubitemid 19100712)
66. Jenkin D, Goddard K, Armstrong D, Becker L, Berry M, Chan H, et al. Posterior fossa medulloblastoma in childhood: treatment results and a proposal for a new staging system. Int J Radiat Oncol Biol Phys 1990;19:265-74. (Pubitemid 20299017)
67. Judkins AR. Immunohistochemistry of INI1 expression: a new tool for old challenges in CNS and soft tissue pathology. Adv Anat Pathol 2007;14:335-9. (Pubitemid 47312288)
68. Kao GD, Goldwein JW, Schultz DJ, Radcliffe J, Sutton L, Lange B. The impact of perioperative factors on subsequent intelligence quotient deficits in children treated for medulloblastoma/posterior fossa primitive neuroectodermal tumors. Cancer 1994;74:965-71. (Pubitemid 24237482)
69. Kieffer-Renaux V, Viguier D, Raquin MA, Laurent-Vannier A, Habrand JL, Dellatolas G, et al. Therapeutic schedules influence the pattern of intellectual decline after irradiation of posterior fossa tumors. Pediatr Blood Cancer 2005;45:814-9. (Pubitemid 41416492)
70. Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, DiGiovanna JJ, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997;69:299.
71. Kleihues P, Cavenee WK. World Health Organisation Classification of tumors. Pathology and genetics: tumors of the nervous system. Lyon: IARC Press; 2000.
72. Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, et al. J Clin Oncol. 2010; 28(18): p. 3054-60.
73. Kortmann RD, Kuhl J, Timmermann B. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood. Int J Radiat Onocol Biol Phys 2000;46:269-79. (Pubitemid 30067775)
74. Krischer JP, Ragab AH, Kun L, Kim TH, Laurent JP, Boyett JM, et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Study Group. J Neurosurg 1991;74:905-9.
75. Kühl J. Modern treatment strategies in medulloblastomas. Child Nerv Syst 1998;14:2-5.
76. Kunschner LJ, Kuttesch J, Hess K, Yung WK. Survival and recurrence factors in adult medulloblastoma: the MD Anderson Cancer center experience from 1978 to 1998. Neuro Oncol 2001;3:167-73.
77. Le QT, Weil MD, Wara WM, Lamborn KR, Prados MD, Edwards MS, et al. Adult medulloblastomas: an analysis of survival and prognostic factors. Cancer J Sci Am 1997;3:238-45.
78. Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 1999;91:1051-8. (Pubitemid 29293044)
79. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. Acta Neuropathol 2007; 114: p. 97-109.
80. Merchant TE, Happersett L, Finlay JL, Leibel SA. Preliminary results of conformal radiation therapy for medulloblastoma. Neurooncol 1999;1:177-87.
81. Merchant TE, Kun LE, Krasin MJ, Wallace D, Chintagumpala MM, Woo SY, Ashley DM, Sexton M, Kellie SJ, Ahern V, Gajjar A. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys 2008;70:782-7. (Pubitemid 351199711)
82. Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 2002;54:824-9.
83. Moschovi M, Sotiris Y, Prodromou N, Tsangaris GT, Constantinidou Van-Vliet C, et al. Familial medulloblastoma. Pediatr Hematol Oncol 1998;15:421-4. (Pubitemid 28450315)
84. Mostow EN, Byrne J, Connelly RR, Mulvihill JJ. Quality of life in long-term survivors of CNS tumors of childhood and adolescence. J Clin Oncol 1991;9:592-9.
85. Mulhern RK, Kepner JL, Thomas PR, Armstrong FD, Friedman HS, Kun LE. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Study Group. J Clin Oncol 1998;16:1723-8.
86. Mulhern RK, Palmer SL, Reddick WE. Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol 2001;19:472-9. (Pubitemid 32112861)
87. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 2004;64:3103-11. (Pubitemid 38581410)
88. Ogilvy-Stuart A, Clayton P, Shalet S. Cranial irradiation and early puberty. J Clin Endrocrinol Metab 1994;78:1282-6. (Pubitemid 24180992)
89. Olshan JS, Gubernick J, Packer RJ, D'Angio GJ, Goldwein JW, Willi SM, et al. The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer 1992;70:2013-7.
90. Oyharcabal-Bourden V, Kalifa C, Gentet J-C, Frappaz D, Edan C, Chastagner P, et al. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology study. J Clin Oncol 2005;23:4726-34. (Pubitemid 46224076)
91. Packer RJ, Sutton LN, Goldwein JW, Perilongo G, Bunin G, Ryan J, et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 1991;74:433-40.
92. Packer RJ, Goldwein J, Nicholson HS, Vezina LG, Allen JC, Ris MD, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a children's cancer group study. J Clin Oncol 1999;17(7):2127-36. (Pubitemid 29318845)
93. Packer RJ, Gurney JG, Punyko JA, Donaldson SS, Inskip PD, Stovall M, et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. J Clin Oncol 2003;21:3255-61. (Pubitemid 46606258)
94. Packer RJ, Gajjar R, Vezina G, Langston D, Rorke L, Burger P, et al. Preliminary results of a prospective randomized study of "reduced" craniospinal radiotherapy followed by one of two adjuvant chemotherapy regimens for children with medulloblastoma: children's oncology group study. Ann Neurol 2004;56(S8):S89-90.
95. Padovani L, Sunyach MP, Perol D, Mercier C, Alapetite C, Haie-Meder C, et al. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys 2007;68:433-40. (Pubitemid 46694158)
96. Paulino AC. Hypothyroidism in children with medulloblastoma: a comparison of 3600 and 2340 cGy craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 2002;53:543-7. (Pubitemid 34626491)
97. Peterson K, Walker RW. Medulloblastoma/primitive neurectodermal tumor in 45 adults. Neurology 1995;45:440-2.
98. Pettoni BL, Narducci A, de Carlo A, Abet F, Cladarelli M, Massimi L, et al. Thyroid neoplasm after central nervous system irradiation for medulloblastoma in childhood: report of two cases. Child Nerv Syst 2009;25:631-4.
99. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009;27:1627-736.
100. Poelen J, Bernsen HJ, Prick MJ. Metastatic medulloblastoma in an adult; treatment with temozolomide. Acta Neurol Belg 2007;107:51-4. (Pubitemid 47071626)
101. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al. Prediction of central nervous system embryonnal tumor outcome based on gene expression. Nature 2002;415:436-42. (Pubitemid 34100955)
102. Prados MD, Warnick RE, Wara WM, Larson DA, Lamborn K, Wilson CB. Medulloblastoma in adults. Int J Radiat oncol Biol Phys 1995;32:1145-52.
103. Radcliffe J, Bunin GR, Sutton LN, Goldwein JW, Phillips PC. Cognitive deficits in long-term survivors of childhood medulloblastoma and other noncortical tumors: age-dependent effects of whole-brain radiation. Int J Dev Neurosci 1994;12:327-34. (Pubitemid 24217842)
104. Ridola V, Grill J, Doz F, Gentet JC, Frappaz D, Raquin MA, et al. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer 2007;110:156-63. (Pubitemid 46986428)
105. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group Study. J Clin Oncol 2001;19:3470-6. (Pubitemid 32730083)
106. Roberts RO, Lynch CF, Jones MP, Hart MN, Medulloblastoma:. a population-based study of 532 cases. J Neuropathol Exp Neurol 1991;50:134-44.
107. Rochkind S, Blatt I, Sadeh M, Goldhammer Y. Extra-cranial metastases of medulloblastoma in adults: litterature review. J Neurol Neurosurg and Psychiatry 1991;54:80-6.
108. Rodriguez FJ, Eberhart C, O'Neill BP, Slezak J, Burger PC, Goldthwaite P, et al. Histopathologic grading of adult medulloblastomas. Cancer 2007;109:2557-65. (Pubitemid 46906476)
109. Rogers HA, Miller S, Lowe J, Brundler MA, Coyle B, Grundy RG. An investigation ofWNT pathway activation and associationwith survival in cntral nervous system primitive neurectoderma tumors (CNS PET). Br J Cancer 2009;100:1292-302.
110. Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 2004;31:666-75. (Pubitemid 39389018)
111. Rorke LB. The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol 1983;42:1-15. (Pubitemid 13180818)
112. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449. N Eng J Med 2009;361:1173-8.
113. Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soperensen N, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005;352:978-86. (Pubitemid 40349500)
114. Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sörensen N, Kühl J. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 1998;16:2478-85. (Pubitemid 28309044)
115. Sevenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet 1999;65:1342-8. (Pubitemid 30460384)
116. Shalet SM, Gibson B, Swindell R, Pearson D. Effect of spinal irradiation on growth. Arch Dis Child 1987;62:461-4.
117. Shaw DW, Geyer JR, Berger MS, Milstein J, Lindsley KL. Asymptomatic recurrence detection with surveillance scanning in children with medulloblastoma. J Clin Oncol 1997;15:1811-3. (Pubitemid 27209508)
118. Silber JH, Radcliffe J, Peckham V, Perilongo G, Kishnani P, Fridman M, et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol 1992;10:1390-6. (Pubitemid 23059921)
119. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the F U.K. 1959-85: a cohort study. Lancet 2002;360:273-7.
120. Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris-Jones P. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990;26:464-9. (Pubitemid 20209976)
121. Tarbell NJ, Loeffler JS, Siver B, Lynch E, Lavally BL, Kupsky W.J.. et al. The change in patterns of relapse in medulloblastomas. Cancer 1991;68:1600-4.
122. Taylor MD, Liu L, Raffel C, Hui CC, Mainprize TG, Zhang X, et al. Mutations in SUFU predispose to medulloblastoma. Nat Gent 2002;31:354-62.
123. Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 2003;21(8):1581-91. (Pubitemid 46594113)
124. Thomas PR, Deutsch M, Kepner JL, Boyett JM, Krischer J, Aronin P, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000;18:3004-11. (Pubitemid 30644125)
125. Torres CF, Rebsamen S, Silber JH, Sutton LN, Bilaniuk LT, Zimmerman RA, et al. Surveillance scanning of children with medulloblastoma. N Engl J Med 1994;330:892-5. (Pubitemid 24094968)
126. von Hoff K, Hartmann W, von Bueren AO, Gerber NU, Grotzer MA, Pietsch T, et al. Large cell/anaplastic medulloblastoma: Outcome according to myc status, histopathological, and clinical risk factors. Pediatr Blood Cancer 2010;54:369-76.
127. von Hoff K, Tabori U, Baskin B, Shago M, Alon N, Taylor MD, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 2010;28:1345-50.
128. Vortmeyer AO, Stavrou T, Selby D, Li G, Weil RJ, Park WS, et al. Deletion analysis of the adenomatous polyposis coli and PTCH gene loci in patients with sporadic and nevoid basal cell carcinoma syndrome-associated medulloblastoma. Cancer 1999;85:2662-7. (Pubitemid 29272754)
129. Wolden SL, Dunkel IJ, Souweidane MM, Happersett L, Khakoo Y, Schupak K, et al. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma. J Clin Oncol 2003;21:3079-83. (Pubitemid 46606288)
130. Yazigi-Rivard L, Masserot C, Lachenaud J, Diebold-Pressac I, Aprahamian A, Avran D, et al. Childhood medulloblastoma. Arch Pediatr 2008;15:1794-804.
131. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-45. (Pubitemid 29109313)